Asosiy kontentga oʻtish
Maqola

Chemotherapy in metastatic malignant triton tumor: Report on two cases

Nils H. ThoennissenDepartment of Medicine, Hematology and Oncology, University of Münster, D-48149 Münster, Germany. [email protected]Christoph SchliemannPalmetto Hematology OncologyUta BrunnbergDepartment of Medicine, Hematology and Oncology, University of Münster, Albert Schweitzer Str. 33, D-48149 Münster, GermanyEV SchmidtPalmetto Hematology OncologyAnnette StaeblerLars SteggerNuclear Medicine ,Christoph BremerFH MünsterC SchleicherDepartment of Medicine, Hematology and Oncology, University of Münster, Albert Schweitzer Str. 33, D-48149 Münster, GermanyRolf M. MestersDepartments of 1 Medicine, Hematology and Oncology,Carsten Müller‐TidowDepartments of 1 Medicine, Hematology and Oncology,Wolfgang E. BerdelPalmetto Hematology Oncology
2007en
ABI

Annotatsiya

Malignant triton tumor (MTT) is a rare, highly malignant nerve sheath tumor with rhabdomyoblastic differentiation. Initial debulking surgery followed by adjuvant therapy is the current treatment of choice, but has very limited efficacy when optimal cytoreduction is not achieved by surgical procedure. Neoadjuvant therapy for MTT, to potentially facilitate subsequent surgery, eradicate micrometastatic lesions and, therefore, improve the therapeutical outcome, has never before been presented in literature. Here, we report on the multimodal management of two cases of advanced and metastatic MTT. Treatment modalities involved neoadjuvant and adjuvant chemotherapy, surgical resection, and radiation. In both cases, integrated Positron Emission Tomography/Computed Tomography (PET/CT) emerged as an important diagnostic tool for the reliable assessment of MTT response and metabolic remission.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar